دورية أكاديمية
Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.
| العنوان: | Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. |
|---|---|
| المؤلفون: | Yu KD; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.; Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China., Cai YW; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.; Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China., Wu SY; Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China., Shui RH; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China., Shao ZM; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.; Shanghai Key Laboratory of Breast Cancer, Shanghai, 200032, P. R. China. |
| المصدر: | Cancer communications (London, England) [Cancer Commun (Lond)] 2021 Oct; Vol. 41 (10), pp. 968-980. Date of Electronic Publication: 2021 Jul 12. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 101723675 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2523-3548 (Electronic) Linking ISSN: 25233548 NLM ISO Abbreviation: Cancer Commun (Lond) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : [Hoboken, NJ] : Wiley Original Publication: [London] : BioMed Central, [2018]- |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy , Receptors, Estrogen*/metabolism, Biology ; Carrier Proteins ; Female ; Humans |
| مستخلص: | Hormone receptor testing mainly serves the purpose of guiding treatment choices for breast cancer patients. Patients with estrogen receptor (ER)-positive breast cancers show significant response to endocrine therapy. However, the methods to define ER status and eligibility for treatment remain controversial. Despite recent guidelines considering staining ≥1% of tumor nuclei by immunohistology as ER-positive, it has raised concerns on the benefit of endocrine therapy for tumors with ER 1%-10% expression, termed "ER-low positive". This subgroup accounts for 3% to 9% of all patients and is likely to have unique molecular features, and therefore distinct therapeutic response to endocrine therapy compared with ER-high positive tumors. The latest guidelines did not provide detailed descriptions for those patients, resulting in inconsistent treatment strategies. Consequently, we aimed to resolve this dilemma comprehensively. This review discusses molecular traits and recent ER-low positive breast cancer innovations, highlighting molecular-targeted treatment rather than traditional unified endocrine therapy for future basic and clinical research. (© 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.) |
| References: | N Engl J Med. 1978 Jun 1;298(22):1223-8. (PMID: 651963) J Clin Oncol. 2012 Mar 1;30(7):729-34. (PMID: 22291085) Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815) Lab Invest. 2014 Apr;94(4):467-74. (PMID: 24535259) Am J Clin Pathol. 2005 Jan;123(1):16-20. (PMID: 15762275) J Clin Oncol. 2003 Sep 1;21(17):3357-65. (PMID: 12847142) J Clin Oncol. 1999 May;17(5):1474-81. (PMID: 10334533) Br J Cancer. 2020 Oct;123(8):1223-1227. (PMID: 32713939) NPJ Breast Cancer. 2020 Feb 5;6:5. (PMID: 32047851) Arch Pathol Lab Med. 2010 Apr;134(4):606-12. (PMID: 20367311) Cell Death Dis. 2017 Apr 6;8(4):e2732. (PMID: 28383555) Cancer. 1980 Dec 15;46(12 Suppl):2884-8. (PMID: 7448733) Cancer Commun (Lond). 2020 Aug;40(8):329-344. (PMID: 32654419) Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8. (PMID: 12917485) Cancer Res. 2007 Jun 1;67(11):5513-21. (PMID: 17545634) Lancet Oncol. 2021 Feb;22(2):212-222. (PMID: 33460574) Clin Cancer Res. 2018 Jun 15;24(12):2804-2811. (PMID: 29559561) J Clin Oncol. 2016 Jul 1;34(19):2221-31. (PMID: 27044936) Ann Surg Oncol. 2013 Jan;20(1):87-93. (PMID: 22875649) Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23. (PMID: 12829800) N Engl J Med. 2015 Jan 29;372(5):436-46. (PMID: 25495490) Cancer Genet. 2015 Apr;208(4):135-42. (PMID: 25979597) Cancer Commun (Lond). 2020 Apr;40(4):181-193. (PMID: 32291973) J Clin Oncol. 2007 Oct 20;25(30):4772-8. (PMID: 17876012) J Clin Oncol. 2020 Apr 20;38(12):1346-1366. (PMID: 31928404) Cancer Commun (Lond). 2020 Dec;40(12):738-742. (PMID: 33009697) Nat Genet. 2007 May;39(5):655-60. (PMID: 17417639) JAMA Oncol. 2020 Sep 1;6(9):1390-1396. (PMID: 32789480) Oncologist. 2008 Nov;13(11):1134-6. (PMID: 18987048) Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. (PMID: 22763464) J Clin Oncol. 2016 Oct 1;34(28):3400-8. (PMID: 27325862) Ann Oncol. 2014 May;25(5):1004-11. (PMID: 24562447) J Clin Oncol. 2005 Oct 20;23(30):7721-35. (PMID: 16234531) N Engl J Med. 2016 Aug 25;375(8):717-29. (PMID: 27557300) Ann Oncol. 2019 Sep 1;30(9):1437-1447. (PMID: 31218365) N Engl J Med. 2014 Jul 10;371(2):107-18. (PMID: 24881463) Cancer Commun (Lond). 2021 Oct;41(10):968-980. (PMID: 34251757) NPJ Breast Cancer. 2020 Mar 6;6:8. (PMID: 32195331) J Clin Oncol. 2008 May 20;26(15):2473-81. (PMID: 18487567) N Engl J Med. 2018 Jul 12;379(2):111-121. (PMID: 29860917) Lancet. 2020 Mar 7;395(10226):817-827. (PMID: 32145796) Ann Oncol. 2017 Oct 1;28(10):2420-2428. (PMID: 28961844) Clin Cancer Res. 2020 Dec 15;26(24):6523-6534. (PMID: 33008814) Br J Cancer. 1995 Mar;71(3):448-50. (PMID: 7880722) Mod Pathol. 2009 Nov;22(11):1457-67. (PMID: 19734848) Biomaterials. 2012 Jan;33(3):907-15. (PMID: 22048005) Clin Cancer Res. 2015 Jun 15;21(12):2763-70. (PMID: 26078431) Breast Cancer Res Treat. 2009 Jul;116(2):371-8. (PMID: 18941892) J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81. (PMID: 17077359) Lancet Oncol. 2008 Jan;9(1):45-53. (PMID: 18083636) Breast Cancer Res Treat. 2017 Dec;166(3):855-864. (PMID: 28825224) J Clin Oncol. 2021 May 1;39(13):1485-1505. (PMID: 33507815) Oncol Lett. 2017 Oct;14(4):4736-4740. (PMID: 29085474) J Steroid Biochem Mol Biol. 2017 Jul;171:209-217. (PMID: 28412323) J Clin Oncol. 2016 Apr 1;34(10):1134-50. (PMID: 26858339) Breast Cancer Res Treat. 2007;105 Suppl 1:33-43. (PMID: 17912634) Nat Rev Cancer. 2011 Oct 24;11(11):823; author reply 823. (PMID: 22020208) Clin Cancer Res. 2007 Dec 1;13(23):6921-5. (PMID: 18056165) Endocr Rev. 2004 Dec;25(6):869-98. (PMID: 15583021) Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5. (PMID: 18230721) Cancer. 2012 Mar 15;118(6):1498-506. (PMID: 21837669) Mol Cancer. 2013 Feb 04;12:9. (PMID: 23379261) Mol Cell Endocrinol. 2004 Nov 30;227(1-2):53-65. (PMID: 15501584) J Natl Cancer Inst. 2008 Jun 18;100(12):836-7, 844. (PMID: 18544732) Clin Breast Cancer. 2014 Aug;14(4):258-64. (PMID: 24325948) Arch Pathol Lab Med. 1985 Aug;109(8):716-21. (PMID: 3893381) Nat Rev Cancer. 2011 Jul 22;11(8):597-608. (PMID: 21779010) J Clin Oncol. 2007 Sep 1;25(25):3846-52. (PMID: 17679725) N Engl J Med. 2017 Jun 1;376(22):2147-2159. (PMID: 28564564) Clin Breast Cancer. 2018 Feb;18(1):1-8. (PMID: 28712925) J Cell Physiol. 2019 Feb 11;:. (PMID: 30741415) Clin Endocrinol Metab. 1980 Jul;9(2):361-8. (PMID: 6249524) J Clin Oncol. 2019 Jul 1;37(19):1629-1637. (PMID: 30973790) J Clin Oncol. 2020 Dec 1;38(34):3987-3998. (PMID: 32954927) Lancet Oncol. 2021 Jan;22(1):74-84. (PMID: 33387497) Mol Endocrinol. 2001 Aug;15(8):1344-59. (PMID: 11463858) Clin Cancer Res. 2007 Dec 1;13(23):7029-36. (PMID: 18056179) Lancet. 2011 Aug 27;378(9793):771-84. (PMID: 21802721) J Clin Oncol. 2010 Jun 1;28(16):2784-95. (PMID: 20404251) J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. (PMID: 16145046) J Biol Chem. 2006 Jan 27;281(4):1978-85. (PMID: 16314411) |
| معلومات مُعتمدة: | 81672600 National Natural Science Foundation of China; 81722032 National Natural Science Foundation of China; 82072916 National Natural Science Foundation of China; 2018 Shanghai Youth Excellent Academic Leader; Fudan ZHUOSHI Project |
| فهرسة مساهمة: | Keywords: breast cancer; endocrine therapy; estrogen receptor-low; immunohistochemistry; intrinsic subtype |
| المشرفين على المادة: | 0 (Carrier Proteins) 0 (Receptors, Estrogen) |
| تواريخ الأحداث: | Date Created: 20210712 Date Completed: 20211021 Latest Revision: 20211022 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8504145 |
| DOI: | 10.1002/cac2.12191 |
| PMID: | 34251757 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!